Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024...
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Ipsen enters into an option...
Ipsen publishes its 2023 Universal Registration Document Ipsen publishes its 2023 Universal Registration Document PARIS, FRANCE, 17 April...
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle...
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors Ipsen secures exclusive global...
Ipsen S.A. publishes its 2023 Consolidated Financial Statements Ipsen S.A. - 2023 Consolidated Financial Statements Attachment Ipsen...
Ipsen reçoit l’approbation de la FDA pour le schéma thérapeutique incluant Onivyde®, un potentiel nouveau traitement de référence en première...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.